• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    CaCO3-Assisted Preparation of pH-Responsive Immune-Modulating Nanoparticles for Augmented Chemo-Immunotherapy

    2021-01-18 07:23:34YujieZhuZhijuanYangZiliangDongYimouGongYuHaoLonglongTianXianzhuYangZhuangLiuLiangzhuFeng
    Nano-Micro Letters 2021年2期

    Yujie Zhu, Zhijuan Yang, Ziliang Dong, Yimou Gong, Yu Hao, Longlong Tian, Xianzhu Yang, Zhuang Liu , Liangzhu Feng

    ABSTRACT Due to the negative roles of tumor microenvironment (TME) in compromising therapeutic responses of various cancer therapies, it is expected that modulation of TME may be able to enhance the therapeutic responses during cancer treatment. Herein, we develop a concise strategy to prepare pH-responsive nanoparticles via the CaCO3-assisted double emulsion method, thereby enabling effective co-encapsulation of both doxorubicin (DOX), an immunogenic cell death (ICD) inducer, and alkylated NLG919 (aNLG919), an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1). The obtained DOX/aNLG919-loaded CaCO3 nanoparticles (DNCaNPs) are able to cause effective ICD of cancer cells and at the same time restrict the production of immunosuppressive kynurenine by inhibiting IDO1. Upon intravenous injection, such DNCaNPs show efficient tumor accumulation, improved tumor penetration of therapeutics and neutralization of acidic TME. As a result, those DNCaNPs can elicit effective anti-tumor immune responses featured in increased density of tumor-infiltrating CD8+ cytotoxic T cells as well as depletion of immunosuppressive regulatory T cells (Tregs), thus effectively suppressing the growth of subcutaneous CT26 and orthotopic 4T1 tumors on the Balb/c mice through combined chemotherapy & immunotherapy. This study presents a compendious strategy for construction of pH-responsive nanoparticles, endowing significantly enhanced chemo-immunotherapy of cancer by overcoming the immunosuppressive TME.

    KEYWORDS CaCO3-assisted double emulsion; pH-responsiveness; Neutralization of acidic TME; Immunosuppressive tumor microenvironment modulation; Chemo-immunotherapy

    1 Introduction

    Emerging evidences have shown that the tumor microenvironment (TME) would foist a series of biological barriers to retard effective cancer treatment [1—5]. As a mainstream cancer treatment modality in the clinic, chemotherapy is far from satisfactory due to its limited therapeutic efficacy and severe side effects [6—9]. To achieve effective cancer chemotherapy with high safety, various nanoscale drug delivery systems enabling tumor-targeted delivery of chemotherapeutics have been intensively explored in the past decades [10—13]. Recent progresses have demonstrated that the clinically used nanodrugs, doxil and abraxane, exhibit significantly improved pharmacokinetic behaviors as well as greatly reduced side effects in comparison with their free drug counterparts [14]. However, these nanodrugs still show limited improvements in the therapeutic efficacy owing to the dense extracellular matrix and high interstitial fluid pressure inside the solid tumors, which negatively restrict the intratumoral diffusion of chemotherapeutics [15—18].

    On the other hand, the immunosuppressive TME is another obstacle inside solid tumors that negatively impair the therapeutic efficacy of most chemotherapeutics by disabling the host’s immune system [19—21], even though certain types of chemotherapeutics could induce immunogenic cell death (ICD) to boost the immune attack of tumor cells [22—24]. It has been identified that overexpression of IDO1 is an immunosuppressive feature in a range of tumor types by catalytically converting essential tryptophan (Trp) to kynurenine (Kyn), which is characterized as an immunosuppressive molecule to induce the acquired peripheral tolerance by causing cell cycle arrest and death of effector T cells and in meanwhile activate the immunosuppressive regulatory T cells (Tregs) [25—27]. Recent studies have shown that tumor-targeted delivery of small molecule inhibitors toward the IDO1 could efficiently reverse the tumor immunosuppression and then enhance the therapeutic efficacy of chemotherapy and other cancer treatment modalities by activating the host’s immune system [28—30].

    To overcome the penetration barrier and immunosuppression of TME during treatment of solid tumors, it is meritorious to develop a suitable delivery system to allow co-delivery of ICD stimulus plus IDO1 inhibitors with deep intratumoral penetration to achieve synergistic effects of chemo-immunotherapy. In this study, we developed a concise strategy for the preparation of pH-responsive nanoparticles by introducing CaCO3to the internal water phase during the classical double emulsion method to formulate poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) (PLGA-PEG) nanoparticles (Fig. 1a). By employing the versatile molecular adsorption capacity of CaCO3, the obtained CaCO3@PLGA-PEG nanoparticles (CaNPs) showed significantly improved loading efficiencies to a range of distinct molecules compared to its counterpart PLGA-PEG nanoparticles prepared via the classical method. Then, both doxorubicin (DOX), a chemotherapeutic ICD inducer, and alkylated NLG919 (aNLG919), an inhibitor of IDO1, were simultaneously encapsulated via our CaCO3-assisted double emulsion method, obtaining DOX&aNLG919-coloaded CaNPs (DNCaNPs) with pH-responsive release profiles. It was found that such DNCaNPs after tumor accumulation could enable efficient intratumoral penetration of its therapeutic payloads, which were released when extravasated from the leaky blood vessels into the acidic tumor mass, in meanwhile neutralize the acidic TME by reacting with protons within solid tumors. Moreover, such DNCaNPs upon administration could not only directly cause effective ICD of cancer cells and then elicit the host’s antitumor immunity, but also reduce the density of immunosuppressive Tregs inside TMEs by synergistically inhibiting IDO1 and neutralizing tumor acidity. As a result, superior tumor growth suppression effects could be achieved by intravenous (i.v.) injection of DNCaNPs for both subcutaneous CT26 colon tumors and orthotopic 4T1 breast tumors. Consequently, this study presents a compendious CaCO3-assisted method for the preparation of pH-responsive nanomedicine with profound TME modulation effect for efficient chemo-immunotherapy of cancer.

    2 Experimental

    2.1 Materials

    Fig. 1 Preparation and characterization of the DNCaNPs. a A scheme illustrating the preparation process of such DNCaNPs via our proposed CaCO3-assisted double emulsion method. b, c Representative TEM images of DNCaNPs (b) and DNNPs (c). d DLS size distribution behaviors of DNNPs and DNCaNPs. e, f UV—Vis-NIR spectra of DNCaNPs (e) and non-responsive DNNPs without CaCO3 (f) and other formulation as indicated. Insets were the photographs of CaNPs, DNCaNPs, PLGA-PEG, and DNNPs as indicated. g, h DOX release profiles of DCaNPs (g) and DNPs (h) incubated at pH 7.4, 6.5, and 5.5. i, j aNLG919 release profiles of NCaNPs (i) and NNPs (j) incubated at pH 7.4, 6.5, and 5.5

    PEG5k-PLGA10kwas synthesized according to reported methods [31]. Dodecanoic acid was obtained from MACKLIN. NLG 919 was obtained from PharmaBlock Sciences (Nanjing), Inc. Doxorubicin hydrochloride (DOX) was obtained from Beijing HuaFeng United Technology Co. Ltd. Dichloromethane (CH2Cl2, DCM), sodium bicarbonate (NaHCO3), and CaCl2were obtained from Sinopharm Chemical Reagent Co., Ltd., China. Poly (D,L-lactic-coglycolic acid) (PLGA) and polyvinyl alcohol (PVA) were obtained from Sigma-Aldrich. Antibodies against cell surface markers for flow cytometry assay were purchased from eBioscience. All reagents (analytical grade) were used as received without further purification. Ultrapure water was obtained from a Milli-Q system (Health Force Bio-Meditech Holdings Ltd.).

    2.2 Synthesis of Alkylated NLG919

    To synthesize alkylated NLG919, NLG919 (56 mg, 0.2 mmol) was dissolved in 5 mL DCM followed by being mixed with dodecanoic acid (60 mg, 0.3 mmol), 1-(3-dimethylaminopropyl)-3-ethyl carbon diimine hydrochloride (EDC, 76 mg, 0.4 mmol), 4-dimethylaminopyridine (DMAP, 6 mg, 0.05 mmol), N,N-diisopropyl ethylamine (DIPEA, 83 μL, 0.5 mmol) and stirred at room temperature for 24 h. Then, the product was collected via the vacuum rotary evaporation and re-dissolved with 20 mL DCM and successively washed with hydrochloric acid solution (0.01 M), saturated sodium NaHCO3solution, and saturated NaCl solution before being dried with anhydrous sodium sulfate (Na2SO4). After that, such crude products were obtained by filtration and vacuum distillation and purified by using the column chromatography (eluent: N-hexane/ethyl acetate = 2/1). The obtained final products were confirmed by its1H NMR spectrum and13C NMR spectrum.1H NMR (600 MHz, CDCl3) δ 7.71 (s, 1H), 7.54 (d, J = 7.8 Hz, 1H), 7.52 (d, J = 7.8 Hz, 1H), 7.35 (t, J = 7.8 Hz, 1H), 7.24 (d, J = 7.8 Hz, 1H), 7.17 (s, 1H), 5.09—5.07 (m, J = 1H), 5.06—5.04 (m, 1H), 2.39—2.34 (m, 1H), 2.27- 2.16 (m, 2H), 2.12—2.07 (m, 1H), 1.74—1.71 (m, 2H), 1.65—1.64 (m, 3H), 1.59—1.54 (m, 2H), 1.50—1.46 (m, 1H), 1.27—1.08 (m, 19H), 1.02—0.95 (m, 2H), 0.87 (t, J = 7.2 Hz, 3H).13C NMR (151 MHz, CDCl3) δ 173.51, 144.52, 137.55, 131.38, 130.12, 128.66, 126.63, 124.18, 120.29, 118.62, 73.50, 57.79, 42.26, 37.95, 34.43, 32.02, 29.83, 29.71, 29.60, 29.44, 29.39, 29.30, 28.72, 28.11, 26.38, 26.07, 25.11, 22.81, 14.24.

    2.3 Preparation and Characterization of the DNCaNPs

    DNCaP nanoparticles were prepared via the modified W1/O/W2 double emulsion method. In brief, to prepare emulsion A or B, 250 μL of NaHCO3aqueous solution (0.625 M) or CaCl2aqueous solution (1.25 M, with 1 mg DOX) was added to 750 μL of DCM containing PLGA (15 mg mL-1), PLGA-PEG (15 mg mL-1), and aNLG919 (4 mg mL-1), respectively, before being sonicated using an probe sonicator for 99 pulses (pulses on: 3 s, pulse off: 7 s). Then, emulsion A and emulsion B were mixed and sonicated using the probe sonicator for 99 pulses as aforementioned, obtaining emulsion C to be dropwisely added to 3 mL of PVA solution (1 wt%) under a water bath sonicator for 5 min and stirred at room temperature overnight to evaporate DCM. After that, the obtained DNCaNPs were washed three times by centrifugation at 14,800 rpm for 30 min to remove excess PVA and free drugs, followed by being centrifuged at 3000 rpm for 5 min to remove unwanted large particles. Other control nanoparticles used in this study were prepared via the same procedure apart from corresponding components that were not added.

    The morphologies of the DNCaNPs were observed using a Tecnai F20 transmission electron microscope (TEM). The UV—Vis—NIR spectrum and dynamic light scattering (DLS) size distribution of DNCaNPs were measured by using an UV—Vis spectrometer (GENESYS? 10S, Thermo) and a Malvern Zetasizer (Nano ZS90 Malvern), respectively. The amounts of DOX were quantified by recording their absorbance at 490 nm with a molar extinction coefficient of 10,500 mol-1L cm-1as our previously used methods [32]. The amounts of aNLG919 were quantified by recording their absorbance at 280 nm with a molar extinction coefficient of 17,431 mol-1L cm-1.

    2.4 pH-Responsive DOX and aNLG919 Release Profile of DNCaNPs

    To examine their pH-responsive DOX release profiles, DCaNPs (DOX = 0.5 mg) were transferred to dialysis tubes (molecular weight cutoff = 3500 Da), which were then immersed in 10 mL buffer solutions at pH 7.4, 6.5, and 5.5 solution and stirred at room temperature. Then, the absorbance of external solvents at 490 nm withdrawn at designated time points was recorded to determine the amounts of released DOX as aforementioned.

    To examine the pH-responsive aNLG919 release profiles, NCaNPs (aNLG919 = 2.5 mg) were transferred to dialysis tubes (molecular weight cut-off = 3500 Da), which were then immersed in 10 mL buffer solutions at pH 7.4, 6.5, and 5.5 solution and stirred at room temperature. Then, the absorbance of external solvents withdrawn at designated time points at 280 nm was recorded to determine the amounts of released aNLG919 as aforementioned.

    2.5 In Vitro Cellular Uptake and Penetration of the DNCaNPs

    CT26 murine colon cancer cells and 4T1 murine breast cancer cells were cultured under the standard conditions (37 °C and 5% CO2). For the preparation of CT26 MCSs, singlecell suspension of CT26 cells (1000 cells / well) was added into the 96-well plate, which was precoated with sterilized 1 wt% agar, and cultured at 37 °C for a week according to the previously reported method [33].

    To evaluate the intracellular trafficking profiles of DNCaNPs, preseeded CT26 cells were incubated with DNCaNPs or non-responsive DNNPs at the same DOX concentration (10 μM) for 1, 2, 4, or 8 h before being washed twice with fresh phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde, counterstained with DAPI (1 μg mL-1) for subsequent microscopic observation.

    To exploit the pH-responsive penetration ability of DNCaNPs, CT26 MCSs at diameters of ~ 400 μm were incubated with DNCaNPs or DNNPs (DOX = 5 μM) at pH 7.4 and 6.5, respectively. These treated CT26 MCSs were collected after 12 h, washed twice with PBS, cryosectioned, and counterstained with DAPI before being subjected to a confocal microscopy (Zeiss LSM 800) as aforementioned.

    2.6 IDO-1 Inhibitory Capacity of DNCaNPs

    To evaluate the IDO inhibitory activity of DNCaNPs, CT26 cells preseeded in a 96-well plate at a density of 5 × 103cells/well were simultaneously incubated with recombinant murine IFN-γ (50 ng mL-1) and various agents for 48 h. Then, the supernatant of each well (150 μL) was transferred to a new 96-well plate, followed by being added with 30% trichloroacetic acid (75 μL) and kept at 50 °C for another 6 h to ensure complete hydrolysis of formed N-formylkynurenine to kynurenine. After that, the supernatants were transferred to another new 96-well plate and incubated with an equal volume of Ehrlich reagent (2% p-dimethylamino-benzaldehyde in glacial acetic acid, w/v) for 10 min at room temperature before recording their absorbance at 490 nm by using a microplate reader.

    To evaluate the ratio of Trp/Kyn in the cell supernatants after different treatments, CT26 cells preseeded in a 24-well plate at a density of 2 × 104cells/well were simultaneously incubated with recombinant murine IFN-γ (50 ng mL-1) and various agents for 48 h. Then, the supernatant of each well (300 μL) was transferred to a new 24-well plate, followed by being added with 30% trichloroacetic acid (150 μL) and kept at 50 °C for another 6 h to precipitate the proteins and ensure complete hydrolysis of formed N-formylkynurenine to kynurenine. After that, the concentrations of both Try and Kyn in the cell supernatants of these CT26 cells were quantitatively determined by high-performance liquid chromatography (HPLC, Thermo, UltiMate 3000).

    2.7 ICD Induction Capacity of DNCaNPs

    To test the extracellular secretion of ATP, CT26 cells were seeded in the 24-well plate at a density of 2 × 104cells/well. After 12-h preincubation, CaNPs, NCaNPs, DcaNPs, and DNCaNPs at a DOX concentration of 5 μM were added and incubated for 24 h. Then, the supernatant of each well was collected with its ATP concentration determined using an ATP assay kit according to manufacturer’s instructions.

    To evaluate CRT expression and HMGB1 release, CT26 cells preseeded in a 24-well plate containing 15-mm-circle glass cover were incubated with free DOX, DNCaNPs, and other indicated materials at an equivalent DOX concentration of 5 μM for 4 or 12 h, respectively. Then, those cells were washed with PBS, fixed with 4% paraformaldehyde, and stained with CRT or HMGB1 primary antibodies and corresponding fluorophore-conjugated secondary antibodies, respectively, according to the manufactures’ procedures.

    2.8 In Vitro Therapeutic Efficacy of DNCaNPs

    To evaluate the cell killing ability of such DNCaNPs, CT26 cells preseeded in the 96-well plate at a density of 1 × 104cells/well were incubated with CaNPs, aNLG919, free DOX, DCaNPs, and DNCaNPs at a series concentration of DOX and corresponding concentrations of aNLG919. 48 h later, the relative cell viabilities after various treatments were determined by the standard methyl thiazolyl tetrazolium (MTT) assay.

    Additionally, when their diameter approached to ~ 400 μm, these CT26 MCSs (n= 5) were incubated with DNCaNPs, DCaNPS, or DNNPs (DOX = 10 μM) at pH 7.4 and 6.5 for 4 days. The optical images of these treated CT26 MCSs were recorded every day, and their diameters were measured using the ImageAnalysis software (PerkinElmer).

    2.9 In Vivo Fluorescence Imaging and Pharmacokinetic Profiles of DNCaNPs

    Female Balb/c mice were obtained from and used under the protocols approved by the Laboratory Animal Center of Soochow University. To establish subcutaneous CT26 tumor model, 2 × 106CT26 cells were subcutaneously injected into the right back of each mouse. To establish orthotopic 4T1 tumor model, 2 × 1064T1 cells were injected into the fat pat of the left mammary gland of each mouse.

    For in vivo fluorescence imaging, CT26 tumor-bearing mice were intravenously injected with DiR-labeled DNCaNPs and DNNPs and imaged under an in vivo imaging system (Lumina III IVIS, PerkinElmer) at designated time points. At 24 h p.i., these mice were killed with their main organs and tumors collected for ex vivo imaging.

    To investigate the pharmacokinetics behavior of DNCaNPs, CT26 tumor-bearing micen= 3) were i.v. injected with 200 μL of DNCaNPs and free DOX at a DOX dose of 5 mg kg-1. After that, blood samples (~ 20 μL) were collected from each mouse at indicated time points and lysed for the measurement of DOX fluorescence intensity under a Thermo Scientific Varioskan Flash microreader.

    For intravital microscopic observation, CT26 tumor-bearing mice were anesthetized and an incision was made around the tumor without injuring the vessels and then attached with a cover slip [34—37]. Subsequently, these mice were i.v. injected with Cy5.5-loaded DNCaNPs or DNNPs and subjected to the confocal microscopy (Zeiss LSM 800) and imaged at designated time intervals.

    2.10 In Vivo Combination Therapy

    For in vivo treatment, subcutaneous CT26 and orthotopic 4T1 tumor-bearing mice were randomly divided into five groups (n= 5) and treated by intravenous injection of saline (group I), CaNPs (group II), NCaNPs (group III), DCaNPs (group IV), and DNCaNPs (group V) at day 0, 3, and 6. The injection doses of DOX and aNLG919 for related groups were 5 and 25 mg kg-1, respectively. Since the beginning of treatment, the length (L) and width (W) of each tumor were recorded using a digital camera and the tumor volume was calculated by using the formula:V=L×W×W/2. The body weight of each mouse was recorded using a digital balance every other day throughout the whole treatment process. At 24 h after the treatments (day 7), one mouse from each group was killed and their tumor was harvested for TUNEL and H&E staining.

    2.11 Analysis of Anti-tumor Mechanism

    To monitor the pH value within tumors, an invasive pH microelectrode (PM-HP5, PreSens) was inserted into the tumors on mice at 0 and 24h post-intravenous injection of CaNPs or PLGA-PEG nanoparticles, respectively (n= 3).

    To evaluate the intratumoral CRT expression and HMGB1 release, 15 CT26 tumor-bearing mice were treated as aforementioned (n= 3). At 24 h after the treatments (day 7), these tumors after various treatments were collected, cryosectioned, and stained for the detection of intratumoral CRT expression and HMGB1 release via the immunofluorescence staining.

    For the analysis of immune responses of these mice after various treatments, a total of 20 mice bearing CT26 tumor were treated as aforementioned (n= 4). At 1 day after the last injection (day 7), those mice were killed with lymph nodes close to the tumor and tumors collected, homogenized, and stained with varying antibodies by following our previously used protocols [38]. For the staining of DCs, these homogenized lymph node suspensions were sequentially stained with anti-CD11c-FITC, anti-CD80-PE, and anti-CD86-APC antibodies before being subjected to flow cytometric analysis. To stain effector T cells, the homogenized tumor mass suspensions were sequentially stained with anti-CD3-FITC, anti-CD4-APC, and anti-CD8-PE antibodies before being subjected to flow cytometric analysis. To stain Tregs, these homogenized tumor mass suspensions were sequentially stained with anti-CD3-FITC, anti-CD4-APC, anti-ForxP3-PE before subjected to flow cytometric analysis. The intratumoral secretion levels of IFN-γ were analyzed using a commercial ELISA kit according to the manufacturer’s protocols.

    2.12 Statistical Analysis

    All the data were presented as mean ± SD. One-way analysis of variance (ANOVA) was used to determine the significance of the difference. Statistical significance was set at *p< 0.05, **p< 0.01, ***p< 0.001.

    3 Results and Discussion

    3.1 Preparation and Characterization of DNCaNPs

    The classical water—oil—water (W1/O/W2) double emulsion method has been commonly utilized for the encapsulation of both hydrophilic and hydrophobic molecules, but its loading efficiency toward hydrophilic molecules may be limited [39]. Herein, by employing the strong adsorption of biocompatible CaCO3to various types of hydrophilic molecules, we developed a novel strategy by introducing CaCO3to the classical double emulsion process, termed as “CaCO3-assisted double emulsion method,” for efficient encapsulation of various hydrophilic molecules (Fig. 1a). After detailed optimization, CaCO3-containing nanoparticles (CaNPs) formulated with a mass feeding ratio of NaHCO3: CaCl2: PLGA: PLGAPEG = 1: 2.6: 2.2: 2.2 were selected for further experiments. Notably, such CaNPs showed greatly improved encapsulation efficiencies toward hydrophilic payloads including DOX (9.1-fold), mitoxantrone (2.1-fold), chlorin e6 (9.8-fold), and bovine serum albumin (BSA, 2.9-fold), compared to those loaded in counterpart PLGA/PLGA-PEG (PLGA-PEG) nanoparticles obtained via the classical method without CaCO3(Fig. S1). Therefore, the greatly improved encapsulation efficiencies of these hydrophilic molecules toward CaNPs should be ascribed to their strong coordination effects with CaCO3according to previous studies [40].

    In addition to loading of hydrophilic molecules, those CaNPs were further loaded with hydrophobic therapeutics. Commercial NLG919 molecules were conjugated with dodecanoic acid to increase its hydrophobicity (Fig. S2). The aNLG919 showed comparable inhibition effect on IDO1, but remarkably elevated encapsulation efficiency in comparison with commercial NLG919 (Figs. S3 and S4). Via simultaneous encapsulation of DOX and aNLG919 into the cavity and polymeric layer, respectively, the obtained DOX&aNLG919 co-loaded CaNPs (DNCaNPs) showed a mean size of 100 nm as visualized under the transmission electron microscopy (TEM) imaging (Fig. 1b). Moreover, we observed clearly dark dots inside such DNCaNPs when we were directly observed via the TEM imaging. These dark dots should be CaCO3nanoparticles formed during the encapsulation process. In contrast, the TEM image of the PLGA/PLGA-PEG formula without CaCO3(DNNPs) showed no dark dots inside (Fig. 1c). It was found that the content of CaCO3in the obtained CaNPs was quantified to be 17.6% by using a commercial calcium colorimetric assay kit, and such CaNPs could rapidly react with proton to neutralize the acidic solutions as expected (Fig. S5). Via the dynamic light scattering (DLS) measurement, such DNCaNPs exhibited similar size distribution profile including mean diameters and polydispersity indexes to its counterpart DNNPs (Fig. 1d and Table S1), and consistent size distribution upon being incubated within H2O, phosphate-buffered saline (PBS), 10% fetal bovine serum (FBS) solution for up to 48 h (Fig. S6a), indicating them with excellent physiological stability. As measured under the UV—Vis spectrometer, the DNCaNPs showed characteristic absorption peaks of aNLG919 and DOX at 280 and 490 nm, respectively (Fig. 1e), indicating their successful encapsulation. The similar result was also observed in DNNPs formula (Fig. 1f).

    Ascribing to the pH-responsive decomposition of CaCO3, such DCaNPs showed more efficient DOX release under acidic pHs, with about 49.3%, 31.0%, and 19.1% of DOX released upon incubation at pH 5.5, 6.5, and 7.4 for 24 h, respectively (Fig. 1g). In sharp contrast, DNPs prepared without introducing CaCO3exhibited similar DOX release behaviors after being incubated in buffers with varying pH values (Fig. 1h). Additionally, relatively slow and continuous aNLG919 release profiles from both NCaNPs and DNPs were observed since aNLG919 was loaded in the hydrophobic PLGA shell, enabling the long-lasting regulation of immune microenvironment in tumor (Fig. 1i, j). Then, the time-dependent size distribution and morphology evolution behaviors of both DNCaNPs and DNNPs incubated at pH 5.5, 6.5, and 7.4 were carefully studied. It was shown that both DNCaNPs and DNNPs exhibited consistent size distribution profiles upon being incubated at varying pHs for up to 24 h as measured via the DLS measurement (Fig. S6b). Under the TEM imaging, obvious small cavities were observed inside such DNCaNPs upon being incubated at pH 5.5 and 6.5 for 24 h, but not observed inside those incubated at pH 7.4 (Fig. S6c). Such distinctive morphology should be ascribed to the acidic pH-induced decomposition of CaCO3inside those DNCaNPs. Taken together, these results demonstrate that such DNCaNP is a promising pH-responsive drug delivery carrier.

    3.2 In Vitro pH-Responsive Cellular Uptake and Penetration Behaviors of DNCaNPs

    Next, the time-lapsed intracellular trafficking profiles of such DNCaNPs were carefully evaluated and compared with that of non-responsive DNNPs by using the confocal laser scanning microscopy (CLSM). It was shown that these murine CT26 cancer cells incubated with both DNCaNPs and DNNPs showed gradually increased DOX fluorescence inside the cytosol. Notably, only cells incubated with DNCaNPs showed remarkably enhanced DOX fluorescence inside the nuclei, the target of DOX, indicating the fast release of DOX from such DNCaNPs upon intracellular internalization (Fig. 2a). By incubating three-dimensional CT26 multicellular spheroids (MCSs) with DNCaNPs and DNNPs at diverse pHs for 12 h, we found that such CT26 MCSs incubated with DNCaNPs at pH 6.5 showed homogenous distribution of DOX fluorescence observed under the CLSM, in sharp contrast to these CT26 MCSs incubated with DNCaNPs at pH 7.4 and DNNPs at pH 6.5 and 7.4 (Fig. 2b). These results indicate that such DNCaNPs could enable efficient pH-responsive intratumoral penetration of therapeutics, which could be attributed to fact that free DOX molecules released from DNCaNPs at low pH would possess better diffusion ability compared to nanoparticles with much larger sizes.

    3.3 Capacities of DNCaNPs in Inhibiting IDO-1 Activity and Inducing Immunogenic Cell Death

    After that, the inhibitory capacity of such DNCaNPs toward IDO1 was carefully evaluated by incubation with IDO1 high-expressed CT26 cells induced by the pretreatment with interferon-gamma (IFN-γ). As measured via the previously reported Ehrlich’s reaction, those pretreated CT26 cells upon incubation with DNCaNPs for 48 h efficiently inhibited Kyn production, which was in proportion to the concentration of aNLG919, similar to those cells treated by the incubation with NCaNPs (Fig. 2c). Moreover, it was further found that the Trp/Kyn ratios in the supernatants of these CT26 cells incubated with DNCaNPs and NCaNPs as aforementioned were also in proportion to the concentration of aNLG919 by recording the concentrations of Trp and Kyn in these supernatants using HPLC (Fig. S7). Then, the capacities of such DNCaNPs in promoting the release of the damage-associated molecular patterns (DAMPs) including adenosine triphosphate (ATP), calreticulin (CRT), and high mobility group box 1 (HMGB1), which were recognized as the markers of ICD, were carefully evaluated on CT26 cells [41, 42]. By utilizing the commercial ATP detection kit, it was shown that those CT26 cells incubated with DNCaNPs and DCaNPs (DOX = 5 μM) for 24 h showed effective release of ATP to the supernatants, while the treatment with CaNPs and NCaNPs showed an minimal effect of ATP release (Fig. 2d). As indicated by corresponding immunofluorescence staining assays, it was shown that those CT26 cells treated by DNCaNPs and DCaNPs both showed effective CRT expression on the plasma membrane and HMGB1 release from the nuclei. In contrast, the incubation with CaNPs and NCaNPs showed negligible influence on the CRT expression and HMGB1 release of those treated cells under the tested conditions (Fig. 2e, f). Based on the above observations, such DNCaNPs can effectively induce ICD of cancer cells.

    Afterward, we carefully investigated the therapeutic efficacy of DNCaNPs using both monolayer CT26 cells and three-dimensional (3D) CT26 MCSs. We found that the half-maximal inhibitory concentration (IC50) of DNCaNPs against monolayer CT26 cells was 1.36 μM, which was comparable to 1.05 and 1.44 μM for free DOX and DCaNPs, respectively, but lower than 3.98 μM for non-responsive DNNPs as measured via the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. In sharp contrast, aNLG919 and plain CaNPs showed a minimal impact on the viability of those cells (Fig. 2g). Furthermore, as monitored under the optical microscopy, it was shown that the growth of 3D CT26 MCSs treated by incubation with both DNCaNPs and DCaNPs (DOX = 10 μM) at pH 6.5 for 4 days was fully regressed compared to those treated by incubation with DNCaNPs and DCaNPs at pH 7.4 or with DNNPs at pH 7.4 and 6.5 (Fig. 2h, i). This result could mainly be attributed to that DOX in the DNCaNPs formulation has the best tumor permeability under acidic conditions owing to its faster pH-responsive release, so it could effectively inhibit the growth of 3D CT26 MCSs from the inside out.

    Fig. 2 In vitro cell experiments. a Confocal images of CT26 cells treated by DNCaNPs and DNNPs for 1, 2, 4, and 8 h. b Representative confocal imaging of CT26 MCSs treated by DNCaNPs or DNNPs at pH 7.4 and 6.5 for 12 h. Scale bar was 200 μm. c In vitro inhibitory effects of DNCaNPs and NCaNPs on the IDO1-mediated Kyn production. d ATP secretion levels of CT26 cells after various treatments as indicated. e, f Confocal microscopic observation of CRT expression (e) and HMGB1 release (f) profiles of CT26 cells with various treatments as indicated. g Cell viability of CT26 cells treated by CaNPs, free aNLG919, free DOX, DNNPs, DCaNPs, and DNCaNPs at various concentrations for 48 h before being measured using the MTT assay. h Optical imaging and i size analysis of CT26 MCSs treated by DNNPs, DCaNPs, and DNCaNPs at pH 7.4 and 6.5. Scale bar is 200 μm

    3.4 In Vivo Pharmacokinetics Profiles of DNCaNPs

    Afterward, we carefully evaluated the in vivo pharmacokinetics profile of such DNCaNPs. After being labeled with near-infrared (NIR) fluorescent dye of 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide (DiR), both DNCaNPs and DNNPs upon intravenous (i.v.) injection were shown to be able to gradually accumulate at the tumor site as visualized using the commercial in vivo optical imaging system (Fig. 3a). By semiquantitatively analyzing the DiR fluorescence intensities of tumor regions, we found that those tumors on the Balb/c mice with systemic administration of DiR-labeled DNCaNPs showed much stronger DiR fluorescence than those injected with DiR-labeled DNNPs (Fig. 3b). The superior tumor-homing capacity of DNCaNPs was further confirmed by recording the DiR fluorescence of tumors collected at 24 h post-systemic administration under the commercial optical imaging system (Figs. 3c and S8). Moreover, by recording the DOX fluorescence, the blood circulation profile of such DNCaNPs was found to follow a two-compartment model, and its first and second half-life times were determined to be 0.32 ± 0.08 and 6.85 ± 0.97 h, respectively, remarkably longer than 0.17 ± 0.05 and 1.81 ± 0.49 h for free DOX (Fig. 3d). By calculation, the area under curve (AUC) values of DNCaNPs and free DOX were determined to be 198.8 and 49.7%ID g-1h, respectively.

    Motived by aforementioned results that such DNCaNPs endowed highly efficient penetration of DOX into 3D CT26 MCSs at pH 6.5, we further carefully studied the penetration capacity of sulfonated cyanine 5.5 (Cy5.5) delivered by both DNCaNPs and DNNPs inside the acidic tumor microenvironment using the intravital microscopy (Fig. 3e). Here, Cy5.5 was utilized as the payload replacing DOX to avoid the interference of autofluorescence from biological tissues. It was shown that the regions aside from the tumor blood vessels within the tumor on mice with i.v. injection of Cy5.5-loaded DNCaNPs exhibited gradually increased Cy5.5 fluorescence intensity, while the Cy5.5 fluorescence was mainly around the tumor blood vessels on those mice injected with Cy5.5-loaded DNNPs (Fig. 3f, g). Taken together, those results indicate that such pH-responsive DNCaNPs is a potent nanocarrier to enable efficient tumor homing and deep intratumoral penetration of their payloads. This process is speculated as that DNCaNPs would firstly accumulate around the vessels through the defective tumor vessels and then release drug molecules in response to the acidic tumor microenvironment. Those released drug molecules with much smaller sizes compared to nanoparticles would then diffuse through tumor vessels and penetrate deeply into tumor tissues.

    3.5 In Vivo Combination Therapy on Subcutaneous CT26 Model

    We then carefully evaluated the in vivo antitumor efficacy of DNCaNPs. When their tumor volumes reached ~ 100 cm3, mice bearing CT26 mouse colon cancer tumors were randomly divided into five groups and received corresponding treatments as follows: group 1, saline injection; group 2, CaNPs injection; group 3, NCaNPs injection; group 4, DCaNPs injection, and group 5, DNCaNPs injection. All mice received three repeated i.v. injections as indicated at day 0, 3, and 6. For corresponding groups, the injection dose of DOX was 5 mg kg-1, while that of aNLG was 25 mg kg-1for each injection (Fig. 4a). It was found that such DNCaNPs most effectively suppress the growth of subcutaneous CT26 tumors with 1 of 5 mice cured, the median survival time of these DNCaNPs treated mice was 40 days (those mice were set as dead when their tumor volume was larger than 1000 mm3, Figs. 4b, c and S9). In contrast, the median survival time of those mice treated by injection of CaNPs, NCaNPs, or DCaNPs were 20, 22, and 26 days, which were only slightly longer than 14 days for mice in the control group.

    Fig. 3 In vivo fluorescence imaging, pharmacokinetics, and tumor penetration behaviors of DNCaNPs. a In vivo fluorescence imaging of CT26 tumor-bearing mice intravenously injected with DiR-labeled DNCaNPs and DNNPs by recording DiR fluorescence. b Semiquantitative analysis of DiR fluorescence intensities of the tumor regions based on the imaging data shown in (a). c Semiquantitative analysis of DiR fluorescence intensities of the main organs as indicated and tumors based on their ex vivo imaging at 24 h post-injection of DiR-labeled DNCaNPs and DNNPs as shown in Fig. S8. d Blood circulation behaviors of DNCaNPs and free DOX as analyzed by measuring DOX fluorescence in the lysed blood samples. e Schematic illustration of the mice prepared for intravital microscopic imaging. f Intravital microscopic observation of time-lapsed extravasation and tumor penetration behaviors of Cy5.5 (as the mimic of DOX) inside the CT26 tumors with intravenous injection of DNCaNPs and DNNPs at designated time intervals. Scale bar is 100 μm. g Semiquantitative analysis of Cy5.5 fluorescence intensities of region of interest (white dashed rectangles) drawn in f

    Moreover, the early therapeutic efficacy of such DNCaNPs was also evaluated via the hematoxylin—eosin (H&E) staining and TdT-mediated dUTP nick-end labeling (TUNEL) staining. It was uncovered that the tumor slice of the mice collected at 1 day after the triple injections (day 7) of DNCaNPs and stained via the TUNEL staining showed effective cell apoptosis, which was much severe than those after other treatments (Fig. 4d). In addition, H&E-stained tumor slices indicated the same trend to that of TUNEL staining, showing most severe histological damages in tumors collected from mice treated by DNCaNPs.

    Fig. 4 In vivo antitumor efficacy and corresponding mechanism study of DNCaNPs mediated chemo- & immunotherapy on subcutaneous CT26 tumor model. a A scheme illustrating the therapeutic schedule. b, c Tumor growth curves (b) and survival curve (c) of these CT26 tumor-bearing mice after being treated as indicated (n = 5). The mouse was set as dead when its tumor volume was over 1000 mm3. d TUNEL and H&E staining of tumor slices collected from the mice with different treatments as indicated at day 7. Scale bars are 200 μm. e Intratumoral pH values of tumors on mice at 0 and 24 h post-intravenous injection of plain CaNPs or PLGA-PEG nanoparticles. f, g Confocal microscopic imaging of tumor slices collected from the mice with different treatments as indicated and stained with CRT (f) and HMGB1 (g) primary antibodies. Scale bars are 1 mm. h, l DC maturation levels in draining LNs (h), intratumoral infiltration frequencies of CD3+ T lymphocytes (i), CD3+CD8+ T cells (j), and CD3+CD4+Foxp3+ Tregs (k), and the ratios of CD3+CD8+ T cells to corresponding CD3+CD4+Foxp3+ Tregs (l) in the CT26 tumors with various treatments as indicated (n = 4). m Intratumoral IFN-γ secretion in the CT26 tumors with various treatments as indicated (n = 3). P values was calculated by using one-way analysis of variance (ANOVA), *p < 0.05, **p < 0.01, ***p < 0.001

    Furthermore, we carefully explored the effects of such DNCaNP treatment on the TME to unfold their highly effective therapeutic efficacy. We speculated that CaCO3nanoparticles could react with H+to neutralize the acidic tumor pH, which is a key feature of TME that leads to immunosuppression [43—45]. In fact, the pH values within tumors on mice with either CaNPs treatment or PLGA-PEG nanoparticles treatment were monitored by an invasive pH microelectrode to confirm the neutralization of acidic tumor microenvironment by CaCO3. Notably, i.v. injection of CaNPs could indeed neutralize the acidic tumor microenvironment at 24 h post-injection, while the injection of PLGA-PEG nanoparticles without CaCO3showed little effect to the pH within tumor (Fig. 4e).

    3.6 Analysis of Antitumor Mechanism

    The capacities of DNCaNPs and other formulations in causing ICD of cancer cells were carefully investigated by evaluating the intratumoral CRT expression and HMGB1 release of these treated tumors collected at 1 day (Day 7) after various treatments. Via the immunofluorescence staining, we found that the treatments of both DNCaNPs and DCaNPs remarkably promoted the expression of CRT and the release of HMGB1, while the other treatments showed limited influence on the CRT expression and HMGB1 release (Fig. 4f, g). Collectively, these results indicated that the treatment of DNCaNPs injections could elicit effective cell death in the ICD manner. Then, the potency of such DNCaNPs mediated ICD of cancer cells in priming antitumor immunity was carefully evaluated by detecting the maturation levels of dendritic cells (DCs), the initial step of antitumor immunity. We found that the maturation status of these DCs isolated from the lymph nodes close to the tumors of these DNCaNP-treated mice was significantly elevated, while the other treatments showed minimal effects on the DC maturation as analyzed at day 7 via the flow cytometry (Figs. 4h and S10a). These results demonstrate that such DNCaNPs are able to induce an effective ICD of cancer cells and thus initiate an effective DC maturation.

    Then, by analyzing the single-cell suspension of the tumors collected from mice with different treatments via the flow cytometry, it was shown that DNCaNPs injection could significantly promote the intratumoral frequencies of CD3+T lymphocytes as well as CD3+CD8+T lymphocytes, while the other treatments exhibited limited influences on the intratumoral frequencies of those T lymphocytes (Figs. 4i, j and S10b). In addition, we found that DNCaNPs injection could remarkably restrict the intratumoral frequency of immunosuppressive Tregs (CD3+CD4+FoxP3+), and the injection of plain CaNPs could even also significantly reduce the intratumoral frequency of Tregs (Figs. 4k and S10c). The latter should be ascribed to the fact that high accumulation of such CaNPs could efficiently neutralize the acidic TME, thereby reducing the intratumoral frequency of Tregs according to the previous study [46]. As a result, the ratio of CD3+CD8+T cells to Tregs inside the tumors grown on the mice treated by DNCaNPs administration was 6.4- and 3.6-folds in comparison with those of the mice treated by saline and DcaNPs injections, respectively (Fig. 4l). Moreover, we found that the secretion level of cytotoxic IFN-γ inside the tumors grown on the DNCaNP treated mice was quantified to 3.2-folds compared to that of control groups, remarkably higher than 1.8-folds for the mice with DCaNPs injection (Fig. 4m). Taken together, those results demonstrated that such DNCaNPs could synergistically prime effective antitumor immune responses as evidenced by the increased DC maturation, elevated frequency of tumorinfiltrating CD3+CD8+T lymphocytes and expression of cytotoxic IFN-γ inside tumors, owing to the DOX-induced immunogenic cancer cell death, the neutralization of acidic TME by CaCO3, as well as NLG-919-mediated reverse of immunosuppressive TME.

    3.7 In Vivo Combination Therapy on Orthotopic 4T1 Model

    Inspired by the high efficacy of such DNCaNPs in priming antitumor immune responses on the subcutaneous CT26 colorectal tumor model, we further investigated the therapeutic potency of such DNCaNPs on the poorly immunogenic orthotopic 4T1 tumor model of triple-negative breast cancer. As being treated by following the therapeutic regimen for those subcutaneous CT26 tumors (Fig. 5a), these orthotopic 4T1 tumors on mice with triple injections of DNCaNPs were the most effectively regressed, and their median survival time was calculated to be 24 days (Figs. 5b, c and S11), while the other treatment showed limited inhibitory effect on those orthotopic 4T1 tumors. Additionally, the superior therapeutic efficacy of such DNCaNPs was further confirmed via the H&E and TUNEL staining of the tumor slices of these tumor-bearing Balb/C mice post-distinct treatments as aforementioned (Fig. 5d). Obvious cell apoptosis and histological damages were observed on these tumor slices of mice post-DNCaNPs treatment via the TUNEL and H&E staining, respectively, indicating that such DNCaNPs would be highly effective for cancer therapy.

    Fig. 5 In vivo antitumor efficacy of the DNCaNP-mediated chemo- & immunotherapy on orthotopic 4T1 tumor models. a A scheme illustrating the therapeutic schedule. b, c Tumor growth curve (b) and corresponding survival curves (c) of these 4T1 tumors on the mice with various treatments as indicated (n = 5). The mouse was set as dead when its tumor volume was over 1000 mm3. d TUNEL and H&E staining of tumor slices collected from the mice with various treatments as indicted at day 7. Scale bar is 200 μm

    Scheme 1 Schematic illustration of the preparation of tumor extracellular pH-responsive immune-modulatable DNCaNPs for effective cancer chemo- & immunotherapy. Upon intravenous injection, such DNCaNPs would passively accumulate at tumor site and rapidly release the loaded DOX in response to the acidic TME, thereby enabling efficient tumor penetration of DOX. Such DOX would induce effective ICD of cancer cells featured in enhanced release of DAMPs of ATP, CRT and HMGB1 as the “eat me” signals to host’s immune system, thus priming the host’s specific antitumor immunity by promoting the maturation of DCs, intratumoral infiltration of effector T cells, and secretion of cytotoxic IFN-γ. In the meantime, tumor-accumulated CaCO3 component would neutralize the acidic TME by reacting with H+ within tumors, and the released aNLG919 would potently inhibit the IDO1-mediated production of immunosuppressive Kyn, thereby synergistically restricting the intratumoral frequency of immunosuppressive Tregs. As a result, such DNCaNPs would prime profound antitumor immune response and efficiently inhibit the tumor growth via the chemo- & immunotherapy

    4 Conclusions

    In this work, we developed a concise CaCO3-assisted double emulsion method to prepare pH-responsive immune-modulating nanoparticles to enable highly efficient chemo-immunotherapy. The introducing of CaCO3could remarkably elevate the loading efficiencies of therapeutic agents compared to conventional PLGA-based delivery systems. Meanwhile, owing to the reaction of CaCO3with H+, those drug-loaded CaNPs with pH-responsive dissociate behaviors not only allow deep intratumoral penetration of therapeutic agents, but also enable effective neutralization of acidic tumor pH to favor the reverse of immunosuppressive TME (Scheme 1).

    With co-loading of chemotherapeutic agent DOX as the ICD inducer and aNLG919 as an IDO1 inhibitor, DNCaNPs after i.v. injection could induce effective immunogenic tumor cell death, thus promoting DCs maturation, CD3+CD8+T lymphocyte infiltration, and cytotoxic IFN-γ secretion, as well as in meanwhile significantly restricting intratumoral frequency of immunosuppressive Tregs. Such reverse in the immunosuppressive TME features could probably be ascribed to NLG919-mediated IDO1 inhibition and CaCO3-mediated neutralization of acidic TME. As a result, DNCaNPs are able to elicit potent antitumor efficacy on these subcutaneous CT26 mouse colon tumors and orthotopic 4T1 triple-negative mouse breast tumors, the latter of which is known to be a poorly immunogenic tumor model resistant to diverse immune stimulation-based treatments [47—49].

    In summary, this work presents a CaCO3-containing nanomedicine formulation that could allow effective modulation of immunosuppressive TME to achieve enhanced chemoimmunotherapy of cancer. Considering that both CaCO3and PLGA-PEG are well known as well biocompatible components, our DNCaNPs would be highly safe and promising for future clinical translation.

    AcknowledgementsThis work was partially supported by the National Natural Science Foundation of China (51802209, 22077093, 51761145041, 51525203), the National Research Programs from Ministry of Science and Technology (MOST) of China (2016YFA0201200), the Natural Science Foundation of Jiangsu Province (BK20180848), the Jiangsu Social Development Project (BE2019658), Collaborative Innovation Center of Suzhou Nano Science and Technology, and the 111 Program from the Ministry of Education of China. We also thank the website of app.Biorender.com for its assistance in the creation of schemes.

    Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons.org/licen ses/by/4.0/.

    Electronic supplementary materialThe online version of this article (https://doi.org/10.1007/s4082 0-020-00549-4) contains supplementary material, which is available to authorized users.

    久久久久久久久久久免费av| 精品一区二区免费观看| .国产精品久久| 可以在线观看毛片的网站| 网址你懂的国产日韩在线| ponron亚洲| 精品一区二区三区人妻视频| 在线a可以看的网站| 日本成人三级电影网站| 国产精品久久久久久精品电影| 欧美日韩乱码在线| 99热只有精品国产| 男人和女人高潮做爰伦理| 日本三级黄在线观看| 又爽又黄a免费视频| 国产探花极品一区二区| 国产一区二区三区av在线 | 国产精品一二三区在线看| 国产日韩欧美在线精品| 国产一级毛片七仙女欲春2| 免费av毛片视频| 哪里可以看免费的av片| 国产真实乱freesex| 国产 一区 欧美 日韩| 91狼人影院| 亚洲av二区三区四区| 插逼视频在线观看| 成年女人看的毛片在线观看| 国产精品久久久久久久电影| 插逼视频在线观看| 亚洲成人久久性| 国产毛片a区久久久久| 国产精品一区二区三区四区免费观看| 美女 人体艺术 gogo| 久久精品久久久久久久性| 国产av一区在线观看免费| 天堂av国产一区二区熟女人妻| 黄色配什么色好看| 久久久久久九九精品二区国产| 村上凉子中文字幕在线| 日日撸夜夜添| 国内精品久久久久精免费| 一本一本综合久久| 精品欧美国产一区二区三| 三级毛片av免费| 亚洲精品456在线播放app| 人妻久久中文字幕网| 一级毛片aaaaaa免费看小| 国产伦在线观看视频一区| 欧美+亚洲+日韩+国产| 国产成人福利小说| 夜夜爽天天搞| 色播亚洲综合网| 高清毛片免费观看视频网站| 精品久久久久久久久久免费视频| 特大巨黑吊av在线直播| 国产av一区在线观看免费| 国产精品野战在线观看| 免费av观看视频| 中文亚洲av片在线观看爽| 精品一区二区免费观看| 一本久久中文字幕| 免费一级毛片在线播放高清视频| 久久欧美精品欧美久久欧美| 日本色播在线视频| 天天躁日日操中文字幕| 亚洲人成网站在线播| 黄色配什么色好看| 久久久成人免费电影| 天天躁日日操中文字幕| 日韩视频在线欧美| 亚洲精品日韩在线中文字幕 | 成年免费大片在线观看| 日韩,欧美,国产一区二区三区 | 青春草亚洲视频在线观看| 欧美xxxx性猛交bbbb| 国产欧美日韩精品一区二区| 蜜臀久久99精品久久宅男| 亚洲无线在线观看| 青春草国产在线视频 | 亚洲精品粉嫩美女一区| 欧美色欧美亚洲另类二区| 97超碰精品成人国产| 久久欧美精品欧美久久欧美| 69av精品久久久久久| 内地一区二区视频在线| 免费观看在线日韩| a级毛片a级免费在线| a级毛色黄片| 国产伦理片在线播放av一区 | 亚洲欧美中文字幕日韩二区| 一级毛片aaaaaa免费看小| 在线观看av片永久免费下载| 一个人免费在线观看电影| 国产精品伦人一区二区| 日本成人三级电影网站| 久久久精品94久久精品| 极品教师在线视频| 全区人妻精品视频| 国产一区二区三区在线臀色熟女| 如何舔出高潮| 国产老妇女一区| 菩萨蛮人人尽说江南好唐韦庄 | 日韩 亚洲 欧美在线| 国产成人午夜福利电影在线观看| 欧美bdsm另类| 国产精品嫩草影院av在线观看| 日韩大尺度精品在线看网址| 村上凉子中文字幕在线| 日韩高清综合在线| 日韩视频在线欧美| 日本色播在线视频| 18禁在线无遮挡免费观看视频| 99久久人妻综合| 插逼视频在线观看| 亚洲精品粉嫩美女一区| 人妻久久中文字幕网| 欧美最新免费一区二区三区| 五月玫瑰六月丁香| 青春草国产在线视频 | 国产一区二区三区在线臀色熟女| 亚洲美女搞黄在线观看| 悠悠久久av| 色综合站精品国产| 99热这里只有精品一区| 国产午夜福利久久久久久| 有码 亚洲区| 久99久视频精品免费| 亚洲成av人片在线播放无| 91aial.com中文字幕在线观看| 亚洲av第一区精品v没综合| 九九爱精品视频在线观看| 国产精品久久久久久久电影| 国产国拍精品亚洲av在线观看| 日韩 亚洲 欧美在线| 色5月婷婷丁香| 久久精品国产自在天天线| 国产成人影院久久av| 免费观看精品视频网站| 日韩中字成人| 国产精品久久久久久精品电影小说 | 久久午夜福利片| 久久久精品大字幕| 婷婷色综合大香蕉| 精品欧美国产一区二区三| 国产成人午夜福利电影在线观看| 99久久精品热视频| 天美传媒精品一区二区| 国产美女午夜福利| 99热这里只有是精品50| 国产黄片美女视频| 欧美+亚洲+日韩+国产| 爱豆传媒免费全集在线观看| 国产高清视频在线观看网站| 美女xxoo啪啪120秒动态图| 久久午夜亚洲精品久久| 嘟嘟电影网在线观看| 精品久久久久久久人妻蜜臀av| 久久久久久久久久久免费av| 黄片无遮挡物在线观看| 九色成人免费人妻av| 一区二区三区免费毛片| 狂野欧美白嫩少妇大欣赏| 乱码一卡2卡4卡精品| 久久鲁丝午夜福利片| 欧美+亚洲+日韩+国产| 亚洲精品色激情综合| av卡一久久| 女人被狂操c到高潮| 久久亚洲国产成人精品v| 3wmmmm亚洲av在线观看| 在线免费十八禁| 欧美高清成人免费视频www| 26uuu在线亚洲综合色| 国产精品久久视频播放| a级一级毛片免费在线观看| 三级经典国产精品| 亚洲国产欧美在线一区| 亚洲欧美精品综合久久99| 熟女电影av网| 国产黄片视频在线免费观看| 欧美最黄视频在线播放免费| 26uuu在线亚洲综合色| 国产午夜精品一二区理论片| 国产精品久久久久久精品电影| 人妻少妇偷人精品九色| 亚洲av二区三区四区| 国产av不卡久久| 成年免费大片在线观看| 我的老师免费观看完整版| 一级二级三级毛片免费看| 蜜桃久久精品国产亚洲av| 12—13女人毛片做爰片一| 欧美一区二区亚洲| 亚洲欧美日韩高清在线视频| 中文欧美无线码| 欧美成人a在线观看| 精品人妻一区二区三区麻豆| 少妇熟女aⅴ在线视频| av天堂在线播放| av在线天堂中文字幕| 老司机影院成人| 亚洲天堂国产精品一区在线| 久久久久国产网址| 最好的美女福利视频网| 又粗又硬又长又爽又黄的视频 | 特大巨黑吊av在线直播| 伦精品一区二区三区| 91午夜精品亚洲一区二区三区| 久久人人爽人人爽人人片va| 亚洲精品久久国产高清桃花| 亚洲国产精品久久男人天堂| 看免费成人av毛片| 亚洲欧美日韩无卡精品| 在线观看美女被高潮喷水网站| 国产乱人偷精品视频| 91久久精品电影网| 成人无遮挡网站| 午夜免费男女啪啪视频观看| 美女国产视频在线观看| 如何舔出高潮| 亚洲真实伦在线观看| 18禁裸乳无遮挡免费网站照片| kizo精华| 天堂√8在线中文| 国产精品蜜桃在线观看 | 美女内射精品一级片tv| 亚洲欧美成人精品一区二区| 美女黄网站色视频| 国产精品久久久久久久久免| 亚洲精品自拍成人| 久久九九热精品免费| 国产成人freesex在线| 亚洲成人中文字幕在线播放| а√天堂www在线а√下载| 欧美丝袜亚洲另类| 国产精品99久久久久久久久| 国产一区二区在线观看日韩| 一级毛片我不卡| 亚洲国产精品国产精品| 亚洲欧美精品自产自拍| a级毛片免费高清观看在线播放| 亚洲国产色片| 国产成人午夜福利电影在线观看| 国产av在哪里看| 国产视频首页在线观看| 男人狂女人下面高潮的视频| 伦理电影大哥的女人| 26uuu在线亚洲综合色| 女人十人毛片免费观看3o分钟| 老司机福利观看| 久久精品国产亚洲av涩爱 | 麻豆精品久久久久久蜜桃| 国产在线男女| 村上凉子中文字幕在线| av卡一久久| 国产久久久一区二区三区| 欧美激情久久久久久爽电影| 国产一区二区在线观看日韩| 插阴视频在线观看视频| 天堂av国产一区二区熟女人妻| 91久久精品电影网| 精品久久久久久久久av| 麻豆av噜噜一区二区三区| 国产伦理片在线播放av一区 | 日日干狠狠操夜夜爽| 亚洲一区高清亚洲精品| 在线观看av片永久免费下载| 国产精品嫩草影院av在线观看| 色综合色国产| 国产黄片视频在线免费观看| 久久亚洲国产成人精品v| 亚洲自偷自拍三级| 国产精品永久免费网站| 少妇被粗大猛烈的视频| 一级黄片播放器| 亚洲人成网站在线播放欧美日韩| 99国产精品一区二区蜜桃av| 亚洲性久久影院| 亚洲18禁久久av| 午夜精品国产一区二区电影 | 春色校园在线视频观看| 亚洲色图av天堂| av在线天堂中文字幕| 大又大粗又爽又黄少妇毛片口| 草草在线视频免费看| a级毛色黄片| 欧美三级亚洲精品| 日韩三级伦理在线观看| 乱系列少妇在线播放| 级片在线观看| 亚洲av二区三区四区| 久久人人爽人人爽人人片va| 少妇人妻精品综合一区二区 | 12—13女人毛片做爰片一| 久久精品综合一区二区三区| 亚洲国产精品成人久久小说 | 欧美性猛交╳xxx乱大交人| 久久草成人影院| 亚洲无线观看免费| 男人舔女人下体高潮全视频| 一本久久中文字幕| 国产激情偷乱视频一区二区| 久久人人精品亚洲av| 色播亚洲综合网| 国产成人精品一,二区 | 可以在线观看的亚洲视频| 国产精品不卡视频一区二区| 亚洲精品成人久久久久久| 一区二区三区免费毛片| 亚洲人成网站在线观看播放| 精华霜和精华液先用哪个| 欧美xxxx黑人xx丫x性爽| 精品国内亚洲2022精品成人| 国产精品av视频在线免费观看| 久久精品国产99精品国产亚洲性色| 国产高潮美女av| 久久久久九九精品影院| 插逼视频在线观看| 18禁裸乳无遮挡免费网站照片| 国内精品一区二区在线观看| 听说在线观看完整版免费高清| 日韩视频在线欧美| 国产成人精品婷婷| 秋霞在线观看毛片| 九九在线视频观看精品| 国产成人影院久久av| 一个人看的www免费观看视频| 18禁在线播放成人免费| 91精品一卡2卡3卡4卡| 九色成人免费人妻av| av在线老鸭窝| 色吧在线观看| 国产精品麻豆人妻色哟哟久久 | 亚洲欧美精品专区久久| 最近的中文字幕免费完整| 永久网站在线| 亚洲av免费高清在线观看| 日本成人三级电影网站| 插阴视频在线观看视频| 亚洲国产高清在线一区二区三| 国产精品久久视频播放| 在线观看免费视频日本深夜| 国模一区二区三区四区视频| 亚洲人成网站在线播放欧美日韩| 高清毛片免费观看视频网站| 免费观看在线日韩| 精品欧美国产一区二区三| 欧美日韩一区二区视频在线观看视频在线 | 欧美xxxx性猛交bbbb| 三级国产精品欧美在线观看| 男人和女人高潮做爰伦理| 欧美日韩一区二区视频在线观看视频在线 | 亚洲综合色惰| 在线免费十八禁| 国产探花极品一区二区| 深夜精品福利| 麻豆乱淫一区二区| 三级经典国产精品| 精品久久久久久久久av| 老司机福利观看| 人妻夜夜爽99麻豆av| 一夜夜www| 国产日韩欧美在线精品| 精品人妻视频免费看| 国产精品久久久久久av不卡| 国产av麻豆久久久久久久| 91av网一区二区| 亚洲欧美日韩高清专用| 熟妇人妻久久中文字幕3abv| www.色视频.com| 在线免费观看不下载黄p国产| 女同久久另类99精品国产91| 国产亚洲av嫩草精品影院| 夜夜看夜夜爽夜夜摸| 男插女下体视频免费在线播放| 国产精品.久久久| 亚洲欧美日韩卡通动漫| 国产精品1区2区在线观看.| av卡一久久| 婷婷精品国产亚洲av| 精品久久久久久久末码| 亚洲国产高清在线一区二区三| 春色校园在线视频观看| 两个人的视频大全免费| 久99久视频精品免费| 男女啪啪激烈高潮av片| 国产亚洲欧美98| 日本五十路高清| 非洲黑人性xxxx精品又粗又长| 亚洲精品日韩在线中文字幕 | 搡女人真爽免费视频火全软件| 人妻久久中文字幕网| 欧美bdsm另类| 国产在视频线在精品| 菩萨蛮人人尽说江南好唐韦庄 | 高清在线视频一区二区三区 | 欧美不卡视频在线免费观看| 一边亲一边摸免费视频| 国产久久久一区二区三区| 日韩av不卡免费在线播放| 卡戴珊不雅视频在线播放| 99热精品在线国产| 精品久久久久久久久亚洲| 99在线视频只有这里精品首页| 久久精品国产亚洲av涩爱 | 国产色婷婷99| 国产一区二区在线观看日韩| 亚洲人与动物交配视频| 欧美最新免费一区二区三区| 国产视频首页在线观看| 老女人水多毛片| 婷婷色综合大香蕉| 51国产日韩欧美| av天堂中文字幕网| 国产精品精品国产色婷婷| 又黄又爽又刺激的免费视频.| 精品久久久久久久久亚洲| 51国产日韩欧美| 夜夜看夜夜爽夜夜摸| 欧美激情在线99| 国产午夜精品论理片| 丰满乱子伦码专区| 国产欧美日韩精品一区二区| 听说在线观看完整版免费高清| 国产精品99久久久久久久久| av卡一久久| 全区人妻精品视频| 乱系列少妇在线播放| 99热网站在线观看| 国产 一区 欧美 日韩| 亚洲国产欧美在线一区| 18+在线观看网站| 成人漫画全彩无遮挡| 日韩国内少妇激情av| 色播亚洲综合网| 欧美区成人在线视频| 好男人在线观看高清免费视频| 大型黄色视频在线免费观看| 成人鲁丝片一二三区免费| 欧美日韩精品成人综合77777| 色尼玛亚洲综合影院| 久久中文看片网| 啦啦啦观看免费观看视频高清| 国产一区二区激情短视频| 中国美白少妇内射xxxbb| 精品免费久久久久久久清纯| 免费av不卡在线播放| 能在线免费看毛片的网站| 亚洲第一区二区三区不卡| 亚洲欧美中文字幕日韩二区| 国内精品美女久久久久久| 久久九九热精品免费| 国产伦精品一区二区三区四那| 美女脱内裤让男人舔精品视频 | 深爱激情五月婷婷| 精品日产1卡2卡| 天天躁夜夜躁狠狠久久av| 亚洲四区av| 欧美不卡视频在线免费观看| 综合色丁香网| 国产伦理片在线播放av一区 | 国产日本99.免费观看| 麻豆久久精品国产亚洲av| 99国产精品一区二区蜜桃av| 免费av观看视频| 精品国产三级普通话版| 国产美女午夜福利| 日韩欧美 国产精品| 日本欧美国产在线视频| 精品不卡国产一区二区三区| 亚洲aⅴ乱码一区二区在线播放| 国产伦精品一区二区三区四那| 亚洲国产精品sss在线观看| 99热全是精品| 亚洲精品日韩在线中文字幕 | 2022亚洲国产成人精品| 精品人妻熟女av久视频| 日韩欧美 国产精品| 亚洲欧美中文字幕日韩二区| 国内精品美女久久久久久| 好男人在线观看高清免费视频| 你懂的网址亚洲精品在线观看 | 女人十人毛片免费观看3o分钟| 久久精品夜色国产| 1000部很黄的大片| 国产片特级美女逼逼视频| 欧美区成人在线视频| 一本一本综合久久| 欧美日韩一区二区视频在线观看视频在线 | 三级经典国产精品| 毛片一级片免费看久久久久| 国产精品.久久久| 日本爱情动作片www.在线观看| 少妇高潮的动态图| 亚洲欧美日韩卡通动漫| 国产精品国产高清国产av| 偷拍熟女少妇极品色| 天天一区二区日本电影三级| 一夜夜www| 日日摸夜夜添夜夜添av毛片| 欧美日韩乱码在线| 成年版毛片免费区| 亚洲精品久久国产高清桃花| 成年女人看的毛片在线观看| 亚洲国产色片| 亚洲成人久久性| 熟女人妻精品中文字幕| 精品人妻偷拍中文字幕| 一进一出抽搐动态| 午夜福利在线观看免费完整高清在 | 给我免费播放毛片高清在线观看| 日韩欧美在线乱码| 国产精品爽爽va在线观看网站| 97超碰精品成人国产| 国产精品福利在线免费观看| 久久精品久久久久久久性| 亚洲欧美精品专区久久| 亚洲成a人片在线一区二区| 亚洲自拍偷在线| 久久精品国产亚洲网站| 91aial.com中文字幕在线观看| a级毛色黄片| 久久欧美精品欧美久久欧美| 国产精品久久视频播放| 久久精品夜色国产| 国产午夜福利久久久久久| 免费观看的影片在线观看| 国产高清不卡午夜福利| 久久久久九九精品影院| 国产午夜福利久久久久久| 美女内射精品一级片tv| 在线播放无遮挡| 美女黄网站色视频| 成人二区视频| 欧美精品一区二区大全| 美女内射精品一级片tv| 亚洲,欧美,日韩| 国产亚洲91精品色在线| 蜜桃久久精品国产亚洲av| 国产极品天堂在线| 国内精品宾馆在线| 不卡视频在线观看欧美| 成人特级av手机在线观看| 国产又黄又爽又无遮挡在线| av免费观看日本| 亚洲成人久久爱视频| 婷婷精品国产亚洲av| 一级毛片电影观看 | 久久久久九九精品影院| 悠悠久久av| 非洲黑人性xxxx精品又粗又长| 国产免费一级a男人的天堂| 日韩av在线大香蕉| 国产成人午夜福利电影在线观看| 热99在线观看视频| 久久精品国产亚洲网站| 欧美日韩综合久久久久久| 狂野欧美激情性xxxx在线观看| 日本在线视频免费播放| 久久99精品国语久久久| 99久国产av精品国产电影| 伦理电影大哥的女人| 欧美性感艳星| 欧美日本视频| 久久久久久国产a免费观看| 中文字幕人妻熟人妻熟丝袜美| 亚洲乱码一区二区免费版| 能在线免费观看的黄片| 在线天堂最新版资源| 欧美激情在线99| 中国美白少妇内射xxxbb| 变态另类丝袜制服| 又爽又黄a免费视频| 美女国产视频在线观看| 天堂网av新在线| 麻豆国产97在线/欧美| 亚洲欧美成人精品一区二区| 精品免费久久久久久久清纯| 九九在线视频观看精品| 国产精品伦人一区二区| 亚洲精品粉嫩美女一区| 变态另类成人亚洲欧美熟女| 麻豆av噜噜一区二区三区| 国产男人的电影天堂91| 亚洲色图av天堂| 日本撒尿小便嘘嘘汇集6| 深夜精品福利| 国产精品.久久久| 免费在线观看成人毛片| 丰满人妻一区二区三区视频av| 日韩国内少妇激情av| 能在线免费观看的黄片| 丰满的人妻完整版| 欧美高清成人免费视频www| 美女cb高潮喷水在线观看| www日本黄色视频网| 欧美变态另类bdsm刘玥| 男人的好看免费观看在线视频| 五月伊人婷婷丁香| 午夜视频国产福利| 春色校园在线视频观看| 欧美bdsm另类| 国产精品不卡视频一区二区| 春色校园在线视频观看| 亚洲av中文av极速乱| 成人亚洲精品av一区二区| 爱豆传媒免费全集在线观看| 中文字幕av在线有码专区| 搡老妇女老女人老熟妇| 国产精品1区2区在线观看.| 1024手机看黄色片| 欧美又色又爽又黄视频| 国产精品蜜桃在线观看 | 久久久色成人|